For additional information, please contact Delora Schneider .
Antibiotics represent the second largest therapeutic category in terms of pharmaceutical sales.
While there are more than 100 different antibiotics from more than 30 different classes approved for use in humans, a select few antibiotics and classes garner the majority of use. Most of the leading products are broad spectrum, with only a few reserved for targeted or restricted use. While the overall market continues to grow at a rate of 6.5 percent, as antibiotics are increasingly used in combination to combat resistant bacteria, no new class of antibiotics has been introduced in twenty years. In 1999, Paratek entered into a collaborative agreement with Glaxo Wellcome plc covering the development and marketing of up to four tetracycline-based novel antibiotics directed at different markets. The agreements provide for equity investments, research support for a period of up to five years, milestone payments, and royalties on worldwide marketing.